These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 25973113)

  • 1. Dedifferentiation-like progression of breast carcinoma: report of a case showing transition from luminal-type carcinoma to triple-negative carcinoma with myoepithelial features.
    Tajima S; Koda K
    Int J Clin Exp Pathol; 2015; 8(2):2117-22. PubMed ID: 25973113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
    Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.
    Nassar A; Sussman ZM; Lawson D; Cohen C
    Breast J; 2012 Sep; 18(5):399-405. PubMed ID: 22882580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant myoepithelioma of the breast.
    Terada T
    Pathol Int; 2011 Feb; 61(2):99-103. PubMed ID: 21255187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status in invasive breast cancer: a 3,198 cases study at National Cancer Center, China.
    Zhu X; Ying J; Wang F; Wang J; Yang H
    Breast Cancer Res Treat; 2014 Oct; 147(3):551-5. PubMed ID: 25234844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma.
    Wiens AL; Martin SE; Bertsch EC; Vance GH; Stohler RA; Cheng L; Badve S; Hattab EM
    Arch Pathol Lab Med; 2014 Feb; 138(2):175-81. PubMed ID: 24476516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Matrix-producing breast carcinoma with myoepithelial differentiation--description of 11 cases and review of literature aimed at histogenesis and differential diagnosis].
    Kinkor Z; Boudová L; Ryska A; Kajo K; Svec A
    Ceska Gynekol; 2004 May; 69(3):229-36. PubMed ID: 15310000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benign myoepithelial tumors of the breast have immunophenotypic characteristics similar to metaplastic matrix-producing and spindle cell carcinomas.
    Popnikolov NK; Ayala AG; Graves K; Gatalica Z
    Am J Clin Pathol; 2003 Aug; 120(2):161-7. PubMed ID: 12931544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ductal carcinoma in situ associated with triple negative invasive breast cancer: evidence for a precursor-product relationship.
    Thike AA; Iqbal J; Cheok PY; Tse GM; Tan PH
    J Clin Pathol; 2013 Aug; 66(8):665-70. PubMed ID: 23539741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benign myoepithelioma of the breast: origin and development.
    Hikino H; Nagaoka S; Miura H; Kurosumi M
    Pathol Int; 2009 Jun; 59(6):422-6. PubMed ID: 19490475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Centrally necrotizing carcinoma of the breast: clinicopathological analysis of 33 cases indicating its basal-like phenotype and poor prognosis.
    Yu L; Yang W; Cai X; Shi D; Fan Y; Lu H
    Histopathology; 2010 Aug; 57(2):193-201. PubMed ID: 20716161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
    Liu H; Fan Q; Zhang Z; Li X; Yu H; Meng F
    Hum Pathol; 2008 Feb; 39(2):167-74. PubMed ID: 18045647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metaplastic variant of invasive micropapillary breast carcinoma: a unique triple negative phenotype.
    Aggarwal G; Reid MD; Sharma S
    Int J Surg Pathol; 2012 Oct; 20(5):488-93. PubMed ID: 22334616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple-negative breast carcinoma in women from Vietnam and the United States: characterization of differential marker expression by tissue microarray.
    Williams DJ; Cohen C; To TV; Page AJ; Lawson D; Sussman ZM; Nassar A
    Hum Pathol; 2009 Aug; 40(8):1176-81. PubMed ID: 19368951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Descriptive analysis of molecular subtypes in Tunisian breast cancer.
    Fourati A; Boussen H; El May MV; Goucha A; Dabbabi B; Gamoudi A; Sfar R; Rahal K; El May A; Ben Abdallah M
    Asia Pac J Clin Oncol; 2014 Jun; 10(2):e69-74. PubMed ID: 23176549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematogenic Dissemination of Triple-negative Versus Hormonal Receptor-positive Breast Cancer Cells.
    Carvalho MJ; Abrantes AM; Laranjo M; Paiva B; Torgal I; Cabrita AS; Botelho F; DE Oliveira CF
    In Vivo; 2015; 29(4):435-44. PubMed ID: 26130788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High incidence and frequency of LOH are associated with aggressive features of high-grade HER2 and triple-negative breast cancers.
    Tokunaga E; Okada S; Yamashita N; Akiyoshi S; Kitao H; Morita M; Kakeji Y; Maehara Y
    Breast Cancer; 2012 Apr; 19(2):161-9. PubMed ID: 21063923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
    Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M
    Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.